Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Kaken’s Axillary Hyperhidrosis Drug, JT’s HIF-PH Inhibitor Up for MHLW Panel Review on Aug. 27
August 17, 2020
- MHLW Urges Trade Groups to Ensure Stable Supply of Povidone-Iodine Products
August 17, 2020
- AstraZeneca to Supply 120 Million Doses of COVID-19 Vaccine to Japan
August 11, 2020
- Japan to Grant Total of 90 Billion Yen to 6 Firms for COVID-19 Vaccine Production
August 11, 2020
- MHLW Warns of COVID-Tied Cyberattacks, Urges Companies to Boost Measures
August 7, 2020
- Tsutomu Iuchi to Lead MHLW's Medical Economics Division
August 6, 2020
- NIBIOHN, US Biotech to Develop COVID-19 Replicon RNA Vaccine; Japan PII Eyed Next Summer
August 5, 2020
- Japan Sketches Out Stable API Supply Measures, Set to Pick Key Drugs from 551 Candidates by March-End
August 4, 2020
- Tetsunari Kihira Appointed as Pharmaceutical Management Director
August 4, 2020
- Pfizer to Supply COVID-19 Vaccine Doses for 60 Million People in Japan
August 3, 2020
- PMDA Reviewing Safety Risks for Plaquenil, Relumina
August 3, 2020
- PMDA Provided Preliminary Info on MID-NET Use for Free in “Just Under 10 Cases”: Official
July 31, 2020
- MHLW Finds 57 Suspected Violations in Drug Detailing Activities in FY2019
July 30, 2020
- AMED’s Drug Discovery Library under CiCLE Program Ready to Start Operations
July 30, 2020
- AMED Selects 2 Anti-COVID-19 Projects under CiCLE Grant Program
July 30, 2020
- HPV Vaccines Clinically Significant in Japan, PMDA Says in Silgard 9 Review Report
July 28, 2020
- Dexamethasone Added to MHLW’s COVID-19 Guide
July 27, 2020
- Chuikyo OKs Plan for September Drug Price Survey, Smaller Coverage amid COVID-19
July 22, 2020
- Reinstate “Active Recommendation” for HPV Vaccines: LDP Lawmakers’ League
July 22, 2020
- Label Revisions Ordered for Iopamiron, 5 Other Contrast Media
July 22, 2020
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…